Development Direction
Development Direction
ADME Improvement
Achieving better distribution of existing drugs through polymer excipients to optimize ADME and change efficacy and toxicity.
LC106
Reversible erythrocyte binding, prolongs circulation time in vivo; tumor tissue permeability is significantly better than PEG modification.
LC201/202
Enables transdermal/oral formulation of specific drugs, such as oral GLP-1, oral chemotherapeutics, transdermal hyaluronic acid, etc.
Nucleic Acid Delivery System
LC301
Enables selectivity for organ targeting of mRNA liposomes for specific expression.
LC302
Based on the latest structure of the research and development system for reducing the dosage of nucleic acid drugs, the dosage of nucleic acid drugs can be reduced by more than a thousand times.
@2022. all rights reserved
About us
